As of 2023, the number of confirmed Rifampicina Resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB) cases in Japan stood at approximately 80 cases. The forecast from 2024 to 2028 suggests stability, with the number of cases consistently projected at 80 annually. This indicates no anticipated increase or decrease in the cases, reflecting a 0% year-on-year variation over these projected years.
Future trends to watch for include potential changes in public health policy, advancements in medical treatments, and variations in disease containment strategies, which could impact the number of RR-/MDR-TB cases beyond the current forecast. Increased international collaboration and data sharing may also influence these numbers by identifying more precise containment and treatment methods.
